Table 5 Association between M-, T- and C- scores and clinical outcome in the two treatment arms of the STOP-IgAN trial (available cases analysis)
From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
M0 events/ total | M1 events/ total | T0 events/ total | T1/2 events/ total | C0 events/ total | C1/2 events/ total | ||
|---|---|---|---|---|---|---|---|
Full clinical remissiona | SUPc | 2/22 (9%) | 0/8 (0%) | 2/15 (13%) | 0/15 (0%) | 1/23 (4%) | 1/7 (14%) |
IMMd | 6/26 (23%) | 0/9 (0%) | 4/24 (17%) | 2/11 (18%) | 3/22 (14%) | 3/13 (23%) | |
GFR-loss ≥15 ml/min | SUP | 7/24 (29%) | 4/8 (50%) | 4/15 (27%) | 7/17 (41%) | 6/24 (25%) | 5/8 (63%) |
IMM | 7/27 (26%) | 5/10 (50%) | 7/25 (28%) | 5/12 (42%) | 10/23 (43%) | 2/14 (15%) | |
ESRDb | SUP | 3/24 (13%) | 1/8 (13%) | 1/15 (7%) | 3/17 (18%) | 1/24 (4%) | 3/8 (38%) |
IMM | 4/27 (15%) | 0/10 (0%) | 0/25 (0%) | 4/12 (33%) | 3/23 (13%) | 1/14 (7%) |